Bio2013 followup report min

  • 260 views
Uploaded on

Meeting report of the Flemish Biotech and Life Sciences week in Japan, now available! Many thanks to the authors and organisers, Flanders Investment & …

Meeting report of the Flemish Biotech and Life Sciences week in Japan, now available! Many thanks to the authors and organisers, Flanders Investment & Trade

www.flandersinvestmentandtrade.be
http://www.novosanis.com/news/flemish-biotech-and-life-sciences-week-japan

More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
260
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Flemish Biotech and Life Sciences Week in Japan 2013 14th Flanders Biotech Seminar in Kobe: TRI, 7 October 2013 14th Flanders Biotech Seminar in Tokyo: Embassy of Belgium, 8 October 2013 BioJapan 2013: Pacifico Yokohama, 9 – 11 October 2013
  • 2. 14th Flemish Biotech Seminar - Kobe 14th Flanders Biotech Seminar in Kobe Monday October 7, 2013 Translational Research Informatics Center Kobe B2B Partnering: 9:30 – 12:00, 13:30 – 18:00 Seminar: 13:30 – 17:50 Reception: 18:00 – 19:30 Organizer: Flanders Investment & Trade / FlandersBio Foundation for Biomedical Research and Innovation / JETRO Kobe Co-organizer: Osaka Pharmaceutical Manufacturers Association Cooperation: Embassy of Belgium / Osaka Chamber of Commerce and Industry Japan Bio Industry Association / Japan Pharmaceutical Manufacturers Association Special Support: Kobe City
  • 3. 14th Flemish Biotech Seminar - Kobe Seminar Attendees Registration 68 Attendees with registration Attendees without registration Final Attendees 51 12 63
  • 4. 14th Flemish Biotech Seminar - Kobe Seminar Program 13:30 – 13:40 Opening Kazuhiko Mori, Managing Director, KOBE CLUSTER, Foundation for Biomedical Research and Innovation (FBRI) Introduction 13:40 – 13:55 FlandersBio “Healthcare biotech in Flanders: a booming industry” Anouk Brackenier, PhD / Project Manager, FlandersBio Academic research and technology transfer 13:55 – 14:10 VIB “VIB, an entrepreneurial research institute: your direct connection to early stage partnering” Lieve Ongena, PhD / Science Policy Manager, VIB Jan Demolder, PhD / European Patent Attorney, VIB
  • 5. 14th Flemish Biotech Seminar - Kobe Drug discovery and development 14:10 – 14:25 arGEN-X “arGEN-X – creating differentiated antibody therapeutics” Tim Van Hauwermeiren, MSc, MBA / Chief Executive Officer, arGEN-X 14:25 – 14:40 reMYND “Novel pre-clinical treatment paradigms for Alzheimer’s disease” Koen De Witte, MSc, MBA / Managing Director, reMYND Development services 14:40 – 14:55 ProDigest “Simulation of the gastrointestinal tract for R&D: the SHIME® technology platform” Massimo Marzorati, PhD / Business Development Director, ProDigest 14:55 – 15:10 Coffee break – 1 Diagnostics 15:10 – 15:25 Biocartis "Biocartis - New Frontiers In Personalized Medicine" Erik Vossenaar, PhD / Director Business Development, BioCartis
  • 6. 14th Flemish Biotech Seminar - Kobe 15:25 – 15:40 MDx Health “Epigenetic Diagnostics for Oncology” Jan Groen, PhD / CEO, MDx Health Drug Delivery/Formulation 15:40 – 15:55 SEPS Pharma “Enhancing the Bioavailability” Jody Voorspoels, PhD / Chief Scientific Officer, SEPS Pharma 15:55 – 16:10 Formac “Overcoming poor drug solubility using ordered mesoporous silicas” Michiel Van Speybroeck, PhD / Chief Scientific Officer, Formac Legal Services 16:10 – 16:25 De Clercq & Partners “Current Challenges and Opportunities in Life Sciences and Pharma IP in the EU” Andrej Michalík, PhD / European Patent Attorney, De Clercq & Partners 16:25 – 16:40 Coffee break - 2
  • 7. 14th Flemish Biotech Seminar - Kobe Session on Devices 16:40 – 16:55 TheraSolve “TheraSolve: The Medication Adherence Innovators” Wim De Geest, MSc / CEO, TheraSolve 16:55 – 17:10 Trinean “Enabling bio-sample quality control with microvolume tools” Yvan Sergeant / Vice President Commercial Operations, Trinean Gustavo Bajotto, PhD / Strategic Marketing, SCRUM 17:10 – 17:25 Novosanis “Novosanis, Medical Device Company: development of a device suited for intradermal vaccination “VAX-ID” and for first void urine collection “Colli-Pee” Vanessa Vankerckhoven, PhD / CEO, Novosanis 17:25 – 17:40 Bruker microCT “High resolution micro-CT in biological and biomedical applications” Jeroen Hostens, PhD / Applications Manager, Bruker microCT 17:40 – 17:50 Closing Ben Kloeck, PhD / Technology Director, Flanders Investment & Trade
  • 8. 14th Flemish Biotech Seminar - Kobe Seminar Kazuhiko Mori Managing Director KOBE CLUSTER, FBRI Anouk Brackenier, PhD Project Manager FlandersBio Lieve Ongena, PhD Science Policy Manager VIB Jan Demolder, PhD European Patent Attorney VIB
  • 9. 14th Flemish Biotech Seminar - Kobe Tim Van Hauwermeiren, MSc, MBA CEO arGEN-X Koen De Witte, MSc, MBA Managing Director reMYND Massimo Marzorati, PhD Business Development Director ProDigest
  • 10. 14th Flemish Biotech Seminar - Kobe Erik Vossenaar, PhD Director Business Development reMYND Jan Groen, PhD CEO MDx Health Jody Voorspoels, PhD Chief Scientific Officer SEPS Pharma Michiel Van Speybroeck, PhD Chief Scientific Officer Formac
  • 11. 14th Flemish Biotech Seminar - Kobe Andrej Michalik, PhD European Patent Attorney De Clercq & Partners Wim De Geest, MSc CEO TheraSolve Yvan Sergeant Vice President Commercial Operations Trinean Gustavo Bajotto, PhD Leader Application Scientist SCRUM (Trinean)
  • 12. 14th Flemish Biotech Seminar - Kobe Vanessa Vankerckhoven, PhD CEO Novosanis Jeroen Hostens, PhD Applications Manager Bruker microCT Ben Kloeck, PhD Technology Director FIT
  • 13. 14th Flemish Biotech Seminar - Kobe
  • 14. 14th Flemish Biotech Seminar - Kobe Reception Hisashi Yamada Chief Director JETRO Kobe Koen De Witte Director, Member of the Board FlandersBio
  • 15. 14th Flemish Biotech Seminar - Kobe
  • 16. 14th Flemish Biotech Seminar - Kobe B2B Partnering • • • 15 Japanese participating companies 11 Flemish participating companies / organization 32 business meetings
  • 17. 14th Flemish Biotech Seminar - Tokyo 14th Flanders Biotech Seminar in Tokyo Tuesday October 8, 2013 Embassy of Belgium Seminar: 13:30 – 17:50 Reception: 18:00 – 19:30 Organizer: Flanders Investment & Trade / FlandersBio Cooperation: Embassy of Belgium / Osaka Chamber of Commerce and Industry Japan Bio Industry Association / Japan Pharmaceutical Manufacturers Association
  • 18. 14th Flemish Biotech Seminar - Tokyo Seminar Attendees Registration 64 Attendees with registration Attendees without registration Final Attendees 44 5 49
  • 19. 14th Flemish Biotech Seminar - Tokyo Seminar H.E. Mr. Luc Liebaut Ambassador of Belgium *Seminar program is same as Kobe
  • 20. 14th Flemish Biotech Seminar - Tokyo
  • 21. 14th Flemish Biotech Seminar - Tokyo
  • 22. 14th Flemish Biotech Seminar - Tokyo
  • 23. 14th Flemish Biotech Seminar - Tokyo Reception
  • 24. 14th Flemish Biotech Seminar - Tokyo
  • 25. 14th Flemish Biotech Seminar – Enquete Analysis • • • • • FIT Tokyo conducted a survey at both the Kobe seminar and Tokyo seminar. About 70% of the participants answered the survey. (44 out of 63 in Kobe, 32 out of 49 in Tokyo) A large number of participants were involved in R&D (39% in Kobe and 47% in Tokyo). There were also a significant number of people from the business development and sales / marketing sector. Most of the participants were satisfied with the quality of the seminar. More than 80% of the respondents both in Kobe and Tokyo answered the seminar as “good” or “very good”. Those who answered “not satisfactory” commented that the focus of technology / business was slightly different from what they were looking for, though the content itself was good. There were wide-ranging interests from the Japanese participants and all presentations were well received.
  • 26. 14th Flemish Biotech Seminar – Enquete Analysis Q1 What is your business field? Immunology 13 6 Infectious diseases 5 3 Diabetes 2 Cardiovascular diseases 2 5 5 Tumor & Cancer 9 7 7 7 Regenerative medicine Cell culture 4 Neurodegeneration Agrobio 0 Bio fuel 0 Clinical research 5 Tokyo 2 5 9 Biomarkers, biotesting Others Kobe 3 0 Compund validation 9 2 1 Nuturaceuticals 10 1 10 2 14 16
  • 27. 14th Flemish Biotech Seminar – Enquete Analysis Q2 What is your job function? 1 Academic research 3 Corporate R&D 12 1 Research management Material / Purchasing 0 2 0 0 Technology / Quality management 16 2 Kobe Business planning / development Sales / Marketing 6 10 6 Consulting 2 Government / Industry organization 2 Others 4 3 3 5 9 Tokyo
  • 28. 14th Flemish Biotech Seminar – Enquete Analysis Q3-1 Are you interested in foreign markets? Kobe Tokyo 0 2 3 4 37 Yes No Unknown 30 Yes No Unknown
  • 29. 14th Flemish Biotech Seminar – Enquete Analysis Q3-2 If yes, in which foreign markets are you interested? 23 24 West Europe 6 East / Central Europe 4 4 Russia China 12 7 India 9 Kobe 12 Tokyo 16 15 Southeast Asia North America Others 10 15 0 3 19
  • 30. 14th Flemish Biotech Seminar – Enquete Analysis Q3-3 Why are you interested in the foreign markets? 4 Setting up business 7 6 Building business relations with local partners 4 13 13 Technology corporation, R&D 8 Local products / Technology Others 10 6 2 Kobe Tokyo
  • 31. 14th Flemish Biotech Seminar – Enquete Analysis Q4-1 How was the seminar? Kobe 8 Tokyo 5 6 9 0 1 0 2 30 15 Very good Good Very good Good Not satisfactory Not good Not satisfactory Not good Unknown Unknown
  • 32. 14th Flemish Biotech Seminar – Enquete Analysis Q4-2 In which presentations are you most interested? FlandersBio 8 VIB 9 14 6 arGEN-X 13 7 12 reMYND 4 ProDigest 7 8 Biocartis MDx Health 3 Formac De Clercq & Partners 12 Kobe 7 4 SEPS Pharma Tokyo 7 3 8 4 15 5 TheraSolve Trinean 8 5 5 9 Novosanis 7 7 Bruker microCT 7 12
  • 33. 14th Flemish Biotech Seminar – Enquete Analysis Q5 How did you find out about the seminar? 14 FIT invitation 7 FIT email Osaka Pharmaceutical Manufacturers Association (OPMA) 14 JETRO Kobe 0 Osaka Chamber of Commerce and Industry (OCCI) 0 Japan Bio Industry Association (JBA) 0 Japan Pharmaceutical Manufacturers Association (JPMA) 0 10 0 Others 9 1 Foundation for Biomedical Research and Innovation (FBRI) 16 Kobe 1 Tokyo 7 3 2 4 6
  • 34. BioJapan 2013 BioJapan 2013 Wednesday 9 October – Friday 11 October 2013 10:00 – 17:00 Pacifico Yokohama Exhibition Hall Organizer: BioJapan Organizing Committee Flemish Participating Companies / Organizations: ADxNeuroSciences, arGEN-X, Biocartis, Bruker microCT, Complix De Clercq & Partners, Formac, MDx Health, Novosanis ProDigest, reMYND, SEPS Pharma, TheraSolve, Trinean VIB, FlandersBio, FIT
  • 35. BioJapan 2013 Fair Visitors 2013 2012 Wed 9/Oct 3,908 3,832 Thu 10/Oct 4,295 4,280 Fri 11/Oct 4,284 4,257 12,487 12,369 Total Fair Exhibitors 2013 2012 23 18 Number of exhibitors 479 403 Foreign exhibitors 129 51 Number of booths 386 351 Number of exhibiting countries and regions
  • 36. BioJapan 2013 Partnering 2013 2012 27 23 607 510 1,054 868 Overseas companies 204 89 Overseas participants 237 106 4,480 3,372 Number of participating countries and regions Number of companies Number of participants Number of meetings
  • 37. BioJapan 2013 Floor Plan FIT booth: B501 (8 unit-booths: 72m2)
  • 38. BioJapan 2013
  • 39. BioJapan 2013
  • 40. BioJapan 2013
  • 41. BioJapan 2013 Visit by Mr. Luc Liebaut, Ambassador of Belgium
  • 42. BioJapan 2013
  • 43. BioJapan 2013
  • 44. BioJapan 2013 Global Partnering Seminar Thu 10/Oct 13:50 – 14:50 • Presentation by FlandersBio, VIB, Complix • Attended by 30+ people
  • 45. BioJapan 2013
  • 46. Flemish Biotech and Life Sciences Week in Japan 2013 For more information concerning the Flemish Biotech and Life Sciences Week in Japan 2013 please contact: Ryoko Fujii Flanders Investment & Trade Tokyo ryoko.fujii@fitagency.com +81 3-5210-5882 www.investinflanders.com